Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response.
As we are confronted with an increasing number of emerging and reemerging viral pathogens, the identification of novel pathogen-specific and broad-spectrum antivirals has become a major developmental objective. Targeting of host factors required for virus replication presents a tangible approach toward obtaining novel hits with a broadened indication range. However, the identification of developable host-directed antiviral candidates remains challenging. We describe a novel screening protocol that interrogates the myxovirus host-pathogen interactome for broad-spectrum drug candidates and simultaneously probes for conventional, pathogen-directed hits. With resource efficiency and pan-myxovirus activity as the central developmental parameters, we explored coscreening against two distinct, independently traceable myxoviruses in a single-well setting. Having identified a pair of unrelated pathogenic myxoviruses (influenza A virus and measles virus) with comparable replication kinetics, we observed unimpaired coreplication of both viruses, generated suitable firefly and Renilla luciferase reporter constructs, respectively, and validated the protocol for up to a 384-well plate format. Combined with an independent counterscreen using a recombinant respiratory syncytial virus luciferase reporter, implementation of the protocol identified candidates with a broadened antimyxovirus profile, in addition to pathogen-specific hits. Mechanistic characterization revealed a newly discovered broad-spectrum lead that does not block viral entry but stimulates effector pathways of the innate cellular antiviral response. In summary, we provide proof of concept for the efficient discovery of broad-spectrum myxovirus inhibitors in parallel to para- and orthomyxovirus-specific hit candidates in a single screening campaign. The newly identified compound provides a basis for the development of a novel broad-spectrum small-molecule antiviral class.
Center for Inflammation, Immunity & Infection, Georgia State University, Atlanta, Georgia, USA.
Dan
D
Yan
Stefanie A
SA
Krumm
Aiming
A
Sun
David A
DA
Steinhauer
Ming
M
Luo
Martin L
ML
Moore
Richard K
RK
Plemper
D000818:Animals; D000998:Antiviral Agents / Q000302:isolation & purification* / Q000494:pharmacology; D002460:Cell Line; D004353:Drug Evaluation, Preclinical / Q000379:methods; D057166:High-Throughput Screening Assays; D054884:Host-Pathogen Interactions / Q000187:drug effects*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D007155:Immunologic Factors / Q000302:isolation & purification* / Q000494:pharmacology; D009980:Influenza A virus / Q000187:drug effects*; D008459:Measles virus / Q000187:drug effects*
D000998:Antiviral Agents; D007155:Immunologic Factors